

## REMARKS/ARGUMENTS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the remarks which follow and the Request for Continued Examination filed herewith.

Claims 1, 14, 15, and 18 are pending in the instant application. Claims 2-13 and 16-17 have been cancelled by the instant amendment or prior amendment(s). Claims 14, 15, and 18 are presently withdrawn from consideration. Amendments to claims 14, 15, and 18 bring the scope of said claims into conformity with the scope of claim 1. No amendments have been made by the instant response.

Claim 1 stands rejected on ground of nonstatutory obviousness-type double patenting as being allegedly unpatentable over claim 1 of U.S. Patent No. 6,632,978.

Enclosed herewith is an executed terminal disclaimer which obviates the pending double patenting rejection.

Claim 1 is therefore believed to be in a condition for allowance.

Applicants request rejoinder of claims 14, 15, and 18 which are directed to processes of using the transgenic mouse of claim 1 and incorporate all of the limitations of claim 1 therein.


Applicants further request rejoinder of claim 9. Claim 9 is directed to subject matter which is classified in the same class and subclass (e.g., class 800, subclass 13) as the subject matter of claim 1 as presently amended.

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3105

Date:

27 June 2007

Respectfully submitted,

  
\_\_\_\_\_  
John Alexander  
Attorney for Applicants  
Reg. No. 48,399